stockrowGilead Sciences, Inc. (GILD) vs Eli Lilly and Company (LLY)
- Gilead Sciences, Inc. GILD 167.78 +0.13%
- Eli Lilly and Company LLY 1,364.51 −0.02%
Gilead Sciences, Inc. and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.28T against $207.8B — 6.2× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Eli Lilly and Company trades at 44.5×. Eli Lilly and Company grew revenue faster over the last twelve months: 45.5% against 6.54%. Eli Lilly and Company has the higher net margin (31.9% vs −12.5%) and the higher return on invested capital (26.4% vs −4.51%). Both pay a dividend; Gilead Sciences, Inc. yields more (1.94% vs 0.49%). Across the 22 metrics below, Eli Lilly and Company leads on 13 and Gilead Sciences, Inc. on 9.
Valuation
Profitability
| Metric | GILD | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 83.64% | 73.01% |
| Operating margin | (7.63%) | 40.27% | 18.34% |
| Net margin | (12.47%) | 31.90% | 7.31% |
| Free cash flow margin | 44.47% | 22.74% | 18.52% |
| Return on equity | (22.45%) | 86.02% | 5.80% |
| Return on assets | (7.03%) | 20.97% | 2.28% |
| Return on invested capital | (4.51%) | 26.42% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack